TrialAssure, a global software company focused on developing clinical trial transparency tools-announced the full release of ANONYMIZE DS, the new software-as-a-service (SaaS) application that utilizes automation to anonymize sponsor’s clinical trial data, during the DIA Global Clinical Trial Disclosure and Data Transparency Conference. Gathering user feedback since its limited release February 2019, TrialAssure ANONYMIZE DS is now fully available to the public.
“As one of the first groups to automate the anonymization of datasets, our developers heard first-hand feedback from industry users during the limited release of the product and fine-tuned ANONYMIZE DS to best meet their needs,” says Zach Weingarden, Product Solutions Manager, TrialAssure. “As with all software we develop, our development team is open to engaging end users, actively encouraging feedback and listening carefully to their suggestions.”
Key features of TrialAssure ANONYMIZE DS, include:
“All pharmaceutical sponsors will need to rely on anonymization methods, and therefore tools, to stay ahead of transparency regulations, as redaction of data limits data utility,” says Mohamad Zahreddine, CIO, TrialAssure, and member of the Forbes Technology Council. “Transparency experts and thoughtful developers have banded together, utilizing the latest technology to build a software application that is of great importance to the future of the pharmaceutical industry, and more broadly, all those in clinical research. We want global teams to #BeTransparent, and it’s in everyone’s best interest that while we must first protect privacy, the data shared should be usable.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.